Peroxisome proliferator-activated receptor γ (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults

Clinical Endocrinology

Volumn 71, Issue 3, 2009, Pages 363-368

  Krag, Morten B ^a   Rasmussen, Lars M ^a   Hansen, Troels K ^a   Frystyk, Jan ^a   Flyvbjerg, Allan ^a   Møller, Niels ^a   Jørgensen, Jens O L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GROWTH HORMONE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 68949218476     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03483.x     Document Type: Article

References (48)

1. Tomlinson, J.W., Holden, N., Hills, R.K. et al 2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425 431.
2. Snel, Y.E., Brummer, R.J., Doerga, M.E. et al. (1995) Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. American Journal of Clinical Nutrition, 61, 1290 1294.
3. Johansson, J.O., Fowelin, J., Landin, K. et al. (1995) Growth hormone-deficient adults are insulin-resistant. Metabolism, 44, 1126 1129.
4. Lakka, H.M., Laaksonen, D.E., Lakka, T.A. et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. The Journal of the American Medical Association, 288, 2709 2716.
5. Hana, V., Silha, J.V., Justova, V. et al. (2004) The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clinical Endocrinology, 60, 442 450.
6. Jorgensen, J.O., Vahl, N., Hansen, T.B. et al. (1996) Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clinical Endocrinology, 45, 681 688.
7. Nielsen, S., Moller, N., Christiansen, J.S. et al. (2001) Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes, 50, 2301 2308.
8. Hansen, T.K., Fisker, S., Dall, R. et al. (2004) Growth hormone increases vascular cell adhesion molecule 1 expression: in vivo and in vitro evidence. Journal of Clinical Endocrinology and Metabolism, 89, 909 916.
9. Takala, J., Ruokonen, E., Webster, N.R. et al. (1999) Increased mortality associated with growth hormone treatment in critically ill adults. New England Journal of Medicine, 341, 785 792.
10. Tepper, R.I., Levinson, D.A., Stanger, B.Z. et al. (1990) IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell, 62, 457 467.
11. Mitsuyama, K., Sasaki, E., Toyonaga, A. et al. (1991) Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion, 50, 104 111.
12. Hack, C.E., De Groot, E.R., Felt-Bersma, R.J. et al. (1989) Increased plasma levels of interleukin-6 in sepsis. Blood, 74, 1704 1710.
13. Kern, P.A., Ranganathan, S., Li, C. et al. (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology - Endocrinology and Metabolism, 280, E745 E751.
14. Pradhan, A.D., Manson, J.E., Rifai, N. et al. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. The Journal of the American Medical Association, 286, 327 334.
15. Heliovaara, M.K., Teppo, A.M., Karonen, S.L. et al. (2005) Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes, Obesity and Metabolism, 7, 729 736.
16. Glund, S., Deshmukh, A., Long, Y.C. et al. (2007) Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes, 56, 1630 1637.
17. Carey, A.L., Steinberg, G.R., Macaulay, S.L. et al. (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes, 55, 2688 2697.
18. Febbraio, M.A., Hiscock, N., Sacchetti, M. et al. (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes, 53, 1643 1648.
19. Krogh-Madsen, R., Plomgaard, P., Keller, P. et al. (2004) Insulin stimulates interleukin-6 and tumor necrosis factor-α gene expression in human subcutaneous adipose tissue. American Journal of Physiology - Endocrinology and Metabolism, 286, E234 E238.
20. Simonet, W.S., Lacey, D.L., Dunstan, C.R. et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309 319.
21. Olesen, P., Ledet, T. Rasmussen, L.M. (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia, 48, 561 568.
22. Browner, W.S., Lui, L.Y. Cummings, S.R. (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. Journal of Clinical Endocrinology and Metabolism, 86, 631 637.
23. Nybo, M. Rasmussen, L.M. (2008) The capability of plasma Osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. European Journal of Endocrinology, 159, 603 608.
24. Rosenblatt, S., Miskin, B., Glazer, N.B. et al. (2001) The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coronary Artery Disease, 12, 413 423.
25. Miyazaki, Y., Mahankali, A., Matsuda, M. et al. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care, 24, 710 719.
26. Ishibashi, M., Egashira, K., Hiasa, K. et al. (2002) Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension, 40, 687 693.
27. Dormandy, J.A., Charbonnel, B., Eckland, D.J. et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366, 1279 1289.
28. Home, P.D., Pocock, S.J., Beck-Nielsen, H. et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine, 357, 28 38.
29. Nissen, S.E. Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine, 356, 2457 2471.
30. Gerrits, C.M., Bhattacharya, M., Manthena, S. et al. (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiology and Drug Safety, 16, 1065 1071.
31. Krag, M.B., Nielsen, S., Guo, Z. et al. (2008) Peroxisome Proliferator-Activated Receptor γ agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. Clinical Endocrinology, 69, 452 461.
32. DeFronzo, R.A., Tobin, J.D. Andres, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology, 237, E214 E223.
33. Hansen, T.K., Thiel, S., Wouters, P.J. et al. (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. Journal of Clinical Endocrinology and Metabolism, 88, 1082 1088.
34. Knudsen, S,T., Foss, C.H., Poulsen, P.L. et al. (2003) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. European Journal of Endocrinology, 149, 39 42.
35. Frystyk, J., Tarnow, L., Hansen, T.K. et al. (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 48, 1911 1918.
36. Frystyk, J., Dinesen, B. Orskov, H. (1995) Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regulation, 5, 169 176.
37. Fried, S.K., Bunkin, D.A. Greenberg, A.S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. Journal of Clinical Endocrinology and Metabolism, 83, 847 850.
38. Bruun, J.M., Verdich, C., Toubro, S. et al. (2003) Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-α. Effect of weight loss in obese men. European Journal of Endocrinology, 148, 535 542.
39. Esteve, E., Castro, A., Lopez-Bermejo, A. et al. (2007) Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care, 30, 939 945.
40. Samaha, F.F., Szapary, P.O., Iqbal, N. et al. (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 624 630.
41. Mohanty, P., Aljada, A., Ghanim, H. et al. (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. Journal of Clinical Endocrinology and Metabolism, 89, 2728 2735.
42. Wallenius, V., Wallenius, K., Ahren, B. et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nature Medicine, 8, 75 79.
43. Glintborg, D., Stoving, R.K., Hagen, C. et al. (2005) Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 5605 5612.
44. Lee, Y.W., Eum, S.Y., Chen, K.C. et al. (2004) Gene expression profile in interleukin-4-stimulated human vascular endothelial cells. Molecular Medicine, 10, 19 27.
45. Gori, A.M., Cesari, F., Marcucci, R. et al. 2009) The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis, 202, 255 262.
46. Fu, M., Zhang, J., Lin, Y.Y. et al. (2002) Activation of peroxisome proliferator-activated receptor γ inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochemical and Biophysical Research Communications, 294, 597 601.
47. Martens, F.M., Rabelink, T.J., op, 'T.R.J., de Koning, E.J. et al. (2006) TNF-α induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-γ agonist pioglitazone. European Heart Journal, 27, 1605 1609.
48. Sesmilo, G., Biller, B.M., Llevadot, J. et al. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine, 133, 111 122.